NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

TSX · Biotechnology · CAD

Sernova Biotherapeutics Inc (SVA.TO) Stock Analysis

Sernova Biotherapeutics Inc (SVA.TO) is a Biotechnology stock listed on TSX and quoted in Canadian Dollar.

SVA.TO

CA$0.11

−CA$0.01 (−8.33%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SVA.TO with… →

SVA.TO Key Statistics

As of Sep 4, 2026
Trading
Open
CA$0.12
Previous Close
CA$0.12
Day's Range
0.11–0.12
52-Week Range
0.10–0.20
Volume
65.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.64
Valuation
Market Cap
CA$41.54M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.04
Financials (FY)
Revenue (FY)
CA$0.00
Net Income (FY)
−CA$15.74M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
377.64M
1-Year Return
−38.89%
Dividend and dates
Earnings Date
September 10, 2026estimated
Avg Volume
107.60K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SVA.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−15.38%
2025−43.48%
2024−67.14%
2023−11.39%
2022−56.59%
2021+171.64%
2020+294.12%
2019−15.00%
2018−52.38%
2017+40.00%
2016 (partial year)−6.25%

As of September 4, 2026.

SVA.TO Revenue and Earnings by Fiscal Year

FY ends October
Fiscal yearRevenueNet incomeNet margin
2025CA$0.00−CA$15.74M—
2024CA$0.00−CA$32.19M—
2023CA$0.00−CA$39.00M—
2022CA$0.00−CA$24.42M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$0.00—−CA$15.02M−CA$15.74M—
2024CA$0.00—−CA$31.66M−CA$32.19M—
2023CA$0.00—−CA$40.50M−CA$39.00M—
2022CA$0.00—−CA$24.75M−CA$24.42M—

Annual figures as reported, in the company's reporting currency. As of October 31, 2025.

SVA.TO Valuation vs Biotechnology Median

Median of 656 stocks
MetricSVA.TOBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Sernova Biotherapeutics Inc (SVA.TO) carries a market capitalisation of CA$41.54M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 8.

Over the past 52 weeks the price has ranged from CA$0.10 to CA$0.20. The most recent close on file for SVA.TO is CA$0.11, dated September 4, 2026. That is −CA$0.01 (−8.33%) against the previous close. The latest close sits 10% above that 52-week low.

Financial Health

In fiscal 2025, Sernova Biotherapeutics Inc reported revenue of CA$0.00. The same year closed with a net loss of CA$15.74M. The reported profit margin is 0%. Trailing earnings per share are −0.04.

Across the 4 fiscal years on file, revenue moves from CA$0.00 in 2022 to CA$0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 0.64. Annualized volatility over the trailing 10 years is 85.74%. Over the trailing twelve months the price has returned −38.89%. Measured over 10 years, that is −9.55% a year compounded.

Growth & Income

The record shows no dividend for SVA.TO.

So far in 2026 the price is −15.38%. Across the complete calendar years on file, 2020 returned +294.12% and 2024 returned −67.14%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Sernova Biotherapeutics Inc (SVA.TO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Sernova Biotherapeutics Inc SVA.TO CA$41.54M —
Vertex Pharmaceuticals Incorporated VRTX CA$138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN CA$85.22B 20.5
argenx SE ARGX CA$64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Sernova Biotherapeutics Inc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Sernova Biotherapeutics Inc

Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc is based in Mississauga, Canada.

Visit website →